Media coverage about Compugen (NASDAQ:CGEN) has trended somewhat negative on Sunday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a coverage optimism score of 0.00 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.7070519134226 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of analysts have recently issued reports on CGEN shares. Zacks Investment Research raised Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. ValuEngine lowered Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
Shares of Compugen (CGEN) opened at $2.80 on Friday. Compugen has a 52-week low of $2.25 and a 52-week high of $5.40. The stock has a market capitalization of $143.17, a PE ratio of -3.94 and a beta of 0.58.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-compugen-cgen-share-price.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.